Spector D H, Boss B D, Strecker R E
Department of Psychiatry and Behavioral Science, SUNY at Stony Brook 11794.
Exp Neurol. 1993 Dec;124(2):253-64. doi: 10.1006/exnr.1993.1195.
Grafts of fetal neural tissue, rich in dopamine (DA) neurons, have previously been shown to improve the symptoms of parkinsonism, both in humans and in animal models. In order to circumvent some of the problems associated with cell transplant therapy, such as the limited availability of transplant tissue, we have established a reaggregate (three-dimensional) tissue culture system that can be used to proliferate normal mammalian neuronal precursors. We demonstrate the in vitro growth of DA-neuronal precursors derived from embryonic porcine ventral mesencephalon, Carnegie stages 15-18. Cultures of DA-neuronal precursors were maintained in F12 medium supplemented with Chang C Supplement for 5 days and switched to serum-free N2 medium for an additional 10 days. Cultures labeled with tritiated thymidine on Days 5-7 in vitro revealed that 43.5% of the DA neurons had incorporated the label, indicative of cell division. Histological examination of the cultured cells demonstrated rosette-like structures, similar to developing neuroepithelium in vivo. Neuronal maturation in vitro was stimulated by dibutyryl cyclic AMP (dbcAMP). Exposure to 5 mM dbcAMP for 7 days stimulated tyrosine hydroxylase (TH), neuron-specific enolase, and 200-kDa neurofilament accumulation three- to sixfold above control levels. After 15 days in vitro, cultured cells reversed amphetamine-induced rotation when grafted into the striata of hemiparkinsonian rats. Successful transplants of cultured neurons were dependent upon a minimum density of DA neurons within the graft (greater than 100 DA neurons/mm3 of graft volume). Data suggest that the percentage of TH neurons can be increased about threefold by culturing the aggregates in tyrosine-free medium, which selects for TH-positive cells. The ability to cultivate mammalian neuronal precursor cells in vitro may eventually make graft therapy a more practical approach to treatment of neurological diseases.
富含多巴胺(DA)神经元的胎儿神经组织移植,此前已证明在人类和动物模型中均可改善帕金森氏症症状。为了规避与细胞移植治疗相关的一些问题,如移植组织供应有限,我们建立了一种重聚集(三维)组织培养系统,可用于增殖正常哺乳动物神经元前体。我们展示了源自胚胎猪腹侧中脑(卡内基分期15 - 18期)的DA神经元前体在体外的生长情况。DA神经元前体培养物在补充了Chang C添加剂的F12培养基中维持5天,然后转换为无血清N2培养基再培养10天。在体外培养的第5 - 7天用氚标记胸腺嘧啶核苷标记培养物,结果显示43.5%的DA神经元摄取了标记物,表明细胞发生了分裂。对培养细胞的组织学检查显示出玫瑰花结样结构,类似于体内发育中的神经上皮。二丁酰环磷腺苷(dbcAMP)刺激了体外神经元的成熟。暴露于5 mM dbcAMP 7天,刺激酪氨酸羟化酶(TH)、神经元特异性烯醇化酶和200 kDa神经丝的积累比对照水平高出三至六倍。体外培养15天后,将培养细胞移植到偏侧帕金森氏症大鼠的纹状体中,可逆转苯丙胺诱导的旋转行为。培养神经元的成功移植取决于移植物内DA神经元的最低密度(大于100个DA神经元/mm³移植物体积)。数据表明,通过在无酪氨酸培养基中培养聚集体来选择TH阳性细胞,TH神经元的百分比可增加约三倍。体外培养哺乳动物神经元前体细胞的能力最终可能使移植治疗成为治疗神经疾病更实用的方法。